Nederlandse Obesitas Kliniek Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2020
NCT04643301
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Nederlandse Obesitas Kliniek | Nederlandse Obesitas Kliniek Zuid | Nederlandse Obesitas Kliniek/Zuyderland Medisch Centrum

Active Ingredients

Drugs in Phase 4 Trials (2)

bupropion (wellbutrin) (1 trial)

naltrexone (revia) (1 trial)

Drugs in Other Trials (1)

liraglutide (victoza) (1 trial)

Indications

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3